Previous 10 | Next 10 |
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annu...
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Bolt Metals Corp. (CSE: BOLT) (FSE: A2QEUB) (OTCQB: PCRCF) (" Bolt " or the " Company ") announces it intends to consolidate the Company's issued share capital on a ratio of one (1) new post-consolidated common share for every te...
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in Februa...
Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q3 GAAP EPS of -$0.58 misses by $0.01 . Revenue of $2.1M (+162.5% Y/Y) beats by $0.87M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.58 misses by $0.01, revenue of $2.1M beats by $0.87...
– BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 – BDC-3042 on track to enter the clinic in 2023; new preclinical data presented at SITC 2022 – Cash balance of $209.6 million anticipated to fund key milestones through 2025 ...
REDWOOD CITY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will be presenting a poster with new preclinical data on BDC-30...
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Stife...
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Morga...
Bolt Biotherapeutics press release ( NASDAQ: BOLT ): Q2 GAAP EPS of -$0.61 beats by $0.08 . Revenue of $1.39M beats by $0.89M . For further details see: Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year – New portfolio prioritization and capital allocation strategy extends expected cash runway by an additional two years – Cash b...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Bolt Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approx...